Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Soliton files 510(k) with FDA for RAP device for reduction of cellulite » 08:05
07/01/20
07/01
08:05
07/01/20
08:05
SOLY

Soliton

$7.79 /

-0.05 (-0.64%)

Soliton announced that it…

Soliton announced that it filed for 510(k) premarket clearance with the U.S. FDA of its second generation Rapid Acoustic Pulse device for the reduction in the appearance of cellulite on June 30. The RAP device was previously cleared by the FDA as an accessory to a 1064 nm Q-switched laser for tattoo removal of black ink on patients with skin tones on the Fitzpatrick scale between I and III.

ShowHide Related Items >><<
SOLY Soliton
$7.79 /

-0.05 (-0.64%)

SOLY Soliton
$7.79 /

-0.05 (-0.64%)

06/16/20 Roth Capital
Soliton price target raised to $16 from $14 at Roth Capital
03/27/20
Fly Intel: Top five analyst initiations
03/27/20 Roth Capital
Soliton initiated with a Buy at Roth Capital
12/05/19 Maxim
Soliton initiated with a Buy at Maxim
SOLY Soliton
$7.79 /

-0.05 (-0.64%)

  • 26
    Jun
SOLY Soliton
$7.79 /

-0.05 (-0.64%)

Over a week ago
Syndicate
Soliton 4.22M share Spot Secondary priced at $8.30 » 09:41
06/26/20
06/26
09:41
06/26/20
09:41
SOLY

Soliton

$11.82 /

+ (+0.00%)

Soliton 4.22M share Spot…

Soliton 4.22M share Spot Secondary priced at $8.30 Cantor Fitzgerald is acting as sole book running manager for the offering.

ShowHide Related Items >><<
SOLY Soliton
$11.82 /

+ (+0.00%)

SOLY Soliton
$11.82 /

+ (+0.00%)

06/16/20 Roth Capital
Soliton price target raised to $16 from $14 at Roth Capital
03/27/20
Fly Intel: Top five analyst initiations
03/27/20 Roth Capital
Soliton initiated with a Buy at Roth Capital
12/05/19 Maxim
Soliton initiated with a Buy at Maxim
SOLY Soliton
$11.82 /

+ (+0.00%)

  • 26
    Jun
SOLY Soliton
$11.82 /

+ (+0.00%)

On The Fly
Fly Intel: Pre-market Movers » 09:03
06/26/20
06/26
09:03
06/26/20
09:03
GPS

Gap

$10.17 /

-0.24 (-2.31%)

, ZGNX

Zogenix

$28.12 /

-0.22 (-0.78%)

, AXSM

Axsome Therapeutics

$76.66 /

+1.22 (+1.62%)

, EKSO

Ekso Bionics

$7.29 /

+4.18 (+134.41%)

, VXRT

Vaxart

$6.26 /

+3.08 (+96.86%)

, BIG

Big Lots

$33.83 /

+0.59 (+1.77%)

, NKE

Nike

$101.46 /

+1.37 (+1.37%)

, APOG

Apogee Enterprises

$22.52 /

+1.19 (+5.58%)

, DBVT

DBV Technologies

$5.40 /

-0.04 (-0.74%)

, SOLY

Soliton

$11.82 /

-0.18 (-1.50%)

, IDEX

Ideanomics

$2.43 /

-0.68 (-21.86%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
ZGNX Zogenix
$28.12 /

-0.22 (-0.78%)

VXRT Vaxart
$6.26 /

+3.08 (+96.86%)

SOLY Soliton
$11.82 /

-0.18 (-1.50%)

NKE Nike
$101.46 /

+1.37 (+1.37%)

IDEX Ideanomics
$2.43 /

-0.68 (-21.86%)

GPS Gap
$10.17 /

-0.24 (-2.31%)

EKSO Ekso Bionics
$7.29 /

+4.18 (+134.41%)

DBVT DBV Technologies
$5.40 /

-0.04 (-0.74%)

BIG Big Lots
$33.83 /

+0.59 (+1.77%)

AXSM Axsome Therapeutics
$76.66 /

+1.22 (+1.62%)

APOG Apogee Enterprises
$22.52 /

+1.19 (+5.58%)

GPS Gap
$10.17 /

-0.24 (-2.31%)

06/22/20 Wells Fargo
Gap rallies after Wells double upgrade on 'compelling value unlocks'
06/08/20 Deutsche Bank
Gap price target lowered to $13 from $15 at Deutsche Bank
06/05/20 MKM Partners
Gap price target raised to $12 from $8 at MKM Partners
06/05/20 RBC Capital
Gap price target raised to $13 from $8 at RBC Capital
ZGNX Zogenix
$28.12 /

-0.22 (-0.78%)

06/26/20 Stifel
FDA approval of Fintepla provides 'sigh of relief' for Zogenix, says Stifel
05/05/20 Piper Sandler
Zogenix price target lowered to $56 from $64 at Piper Sandler
04/22/20 Piper Sandler
Zogenix Fintepla data supports broader utility, says Piper Sandler
04/01/20 Mizuho
Zogenix price target lowered to $64 from $71 at Mizuho
AXSM Axsome Therapeutics
$76.66 /

+1.22 (+1.62%)

04/28/20 Guggenheim
Axsome Therapeutics price target raised to $200 from $158 at Guggenheim
04/28/20 SunTrust
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
04/28/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $131 from $125 at Cantor Fitzgerald
04/28/20 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $200 at H.C. Wainwright
EKSO Ekso Bionics
$7.29 /

+4.18 (+134.41%)

06/26/20 H.C. Wainwright
Ekso Bionics price target raised to $12 from $8 at H.C. Wainwright
01/10/20 H.C. Wainwright
Ekso's Q4 pre-announcement 'bodes well' for 2020 growth, says H.C. Wainwright
10/28/19 H.C. Wainwright
Ekso Bionics initiated with a Buy at H.C. Wainwright
09/06/19 Cantor Fitzgerald
Ekso Bionics initiated with an Overweight at Cantor Fitzgerald
VXRT Vaxart
$6.26 /

+3.08 (+96.86%)

04/30/20 H.C. Wainwright
Vaxart price target raised to $7 from $3 at H.C. Wainwright
08/15/19 Brookline
Vaxart initiated with a Buy at Brookline
06/27/19 H.C. Wainwright
Vaxart initiated with a Buy at H.C. Wainwright
BIG Big Lots
$33.83 /

+0.59 (+1.77%)

06/17/20 Piper Sandler
Piper boosts Big Lots estimates to Street-high, sees 'considerable upside'
05/26/20 Deutsche Bank
Big Lots price target raised to $31 from $19 at Deutsche Bank
05/18/20
Fly Intel: Top five analyst initiations
05/18/20 Goldman Sachs
Big Lots initiated with a Neutral at Goldman Sachs
NKE Nike
$101.46 /

+1.37 (+1.37%)

06/26/20 Morgan Stanley
Market understands Nike's near-term challenges, says Morgan Stanley
06/26/20 Credit Suisse
Nike price target lowered to $111 from $114 at Credit Suisse
06/26/20 UBS
Nike price target raised to $127 from $122 at UBS
06/26/20 Citi
Nike disappointments offset by quarter-to-date performance, says Citi
APOG Apogee Enterprises
$22.52 /

+1.19 (+5.58%)

04/03/20 DA Davidson
Apogee Enterprises price target lowered to $22 from $35 at DA Davidson
12/20/19 DA Davidson
Apogee Enterprises price target lowered to $35 from $40 at DA Davidson
06/28/19 Craig-Hallum
Apogee Enterprises price target raised to $52 after Q1 report at Craig-Hallum
DBVT DBV Technologies
$5.40 /

-0.04 (-0.74%)

06/26/20 Stifel
DBV restructuring 'not comforting for investors,' says Stifel
04/06/20 Citi
DBV's Viaskin Peanut more likely than not to be approved, says Citi
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
03/20/20 Kepler Cheuvreux
DBV Technologies downgraded to Hold from Buy at Kepler Cheuvreux
SOLY Soliton
$11.82 /

-0.18 (-1.50%)

06/16/20 Roth Capital
Soliton price target raised to $16 from $14 at Roth Capital
03/27/20
Fly Intel: Top five analyst initiations
03/27/20 Roth Capital
Soliton initiated with a Buy at Roth Capital
12/05/19 Maxim
Soliton initiated with a Buy at Maxim
IDEX Ideanomics
$2.43 /

-0.68 (-21.86%)

ZGNX Zogenix
$28.12 /

-0.22 (-0.78%)

SOLY Soliton
$11.82 /

-0.18 (-1.50%)

NKE Nike
$101.46 /

+1.37 (+1.37%)

GPS Gap
$10.17 /

-0.24 (-2.31%)

EKSO Ekso Bionics
$7.29 /

+4.18 (+134.41%)

DBVT DBV Technologies
$5.40 /

-0.04 (-0.74%)

BIG Big Lots
$33.83 /

+0.59 (+1.77%)

AXSM Axsome Therapeutics
$76.66 /

+1.22 (+1.62%)

APOG Apogee Enterprises
$22.52 /

+1.19 (+5.58%)

  • 26
    Jun
  • 04
    Mar
  • 30
    Jan
  • 19
    Dec
  • 09
    Oct
ZGNX Zogenix
$28.12 /

-0.22 (-0.78%)

VXRT Vaxart
$6.26 /

+3.08 (+96.86%)

NKE Nike
$101.46 /

+1.37 (+1.37%)

IDEX Ideanomics
$2.43 /

-0.68 (-21.86%)

GPS Gap
$10.17 /

-0.24 (-2.31%)

ZGNX Zogenix
$28.12 /

-0.22 (-0.78%)

VXRT Vaxart
$6.26 /

+3.08 (+96.86%)

NKE Nike
$101.46 /

+1.37 (+1.37%)

IDEX Ideanomics
$2.43 /

-0.68 (-21.86%)

GPS Gap
$10.17 /

-0.24 (-2.31%)

DBVT DBV Technologies
$5.40 /

-0.04 (-0.74%)

BIG Big Lots
$33.83 /

+0.59 (+1.77%)

AXSM Axsome Therapeutics
$76.66 /

+1.22 (+1.62%)

ZGNX Zogenix
$28.12 /

-0.22 (-0.78%)

NKE Nike
$101.46 /

+1.37 (+1.37%)

IDEX Ideanomics
$2.43 /

-0.68 (-21.86%)

GPS Gap
$10.17 /

-0.24 (-2.31%)

BIG Big Lots
$33.83 /

+0.59 (+1.77%)

AXSM Axsome Therapeutics
$76.66 /

+1.22 (+1.62%)

On The Fly
Fly Intel: After-Hours Movers » 19:09
06/25/20
06/25
19:09
06/25/20
19:09
CAMP

CalAmp

$7.69 /

+0.15 (+1.99%)

, SNX

Synnex

$101.60 /

-1.175 (-1.14%)

, PRGS

Progress Software

$37.94 /

+1.16 (+3.15%)

, DKNG

DraftKings

$36.07 /

-1.48 (-3.94%)

, INO

Inovio

$31.33 /

+7.425 (+31.07%)

, NKE

Nike

$101.46 /

+1.37 (+1.37%)

, SOLY

Soliton

$11.82 /

-0.18 (-1.50%)

, MTCH

Match Group

$98.99 /

+0.96 (+0.98%)

Open Full Text

ShowHide Related Items >><<
SOLY Soliton
$11.82 /

-0.18 (-1.50%)

SNX Synnex
$101.60 /

-1.175 (-1.14%)

PRGS Progress Software
$37.94 /

+1.16 (+3.15%)

NKE Nike
$101.46 /

+1.37 (+1.37%)

MTCH Match Group
$98.99 /

+0.96 (+0.98%)

INO Inovio
$31.33 /

+7.425 (+31.07%)

DKNG DraftKings
$36.07 /

-1.48 (-3.94%)

CAMP CalAmp
$7.69 /

+0.15 (+1.99%)

CAMP CalAmp
$7.69 /

+0.15 (+1.99%)

04/17/20 Jefferies
CalAmp upgraded to Buy at Jefferies with downside case seen as priced in
04/17/20 Jefferies
CalAmp upgraded to Buy from Hold at Jefferies
03/26/20 JPMorgan
CalAmp price target lowered to $9 from $12 at JPMorgan
03/06/20 Canaccord
CalAmp price target lowered to $12 from $17 at Canaccord
SNX Synnex
$101.60 /

-1.175 (-1.14%)

05/26/20 Barrington
Synnex price target raised to $115 from $96 at Barrington
04/27/20 Loop Capital
Xerox, Park City, NetApp, HP Enterprise cut to Hold from Buy at Loop Capital
03/25/20 Barrington
Synnex price target lowered to $96 from $150 at Barrington
03/25/20 Cross Research
Synnex downgraded to Hold from Buy at Cross Research
PRGS Progress Software
$37.94 /

+1.16 (+3.15%)

01/17/20 Benchmark
Progress Software price target raised to $57 from $49 at Benchmark
10/22/19 Sidoti
Progress Software initiated with a Buy at Sidoti
09/27/19 Benchmark
Progress Software weakness overdone in after-hours trading, says Benchmark
07/26/19 Wedbush
Progress Software upgraded to Outperform from Neutral at Wedbush
DKNG DraftKings
$36.07 /

-1.48 (-3.94%)

06/25/20 Rosenblatt
DraftKings initiated with a Buy at Rosenblatt
06/24/20 Goldman Sachs
DraftKings price target raised to $34 from $32 at Goldman Sachs
06/22/20
Fly Intel: Top five analyst initiations
06/22/20 Jefferies
DraftKings initiated with a Buy at Jefferies
INO Inovio
$31.33 /

+7.425 (+31.07%)

06/25/20 Piper Sandler
Court denying Inovio injunctive relief 'a major setback,' says Piper Sandler
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/04/20 Cantor Fitzgerald
Inovio, Novavax COVID vaccines should not be disregarded, says Cantor
06/01/20 Piper Sandler
Context 'may be necessary' for Inovio's INO-5401 GBM update, says Piper Sandler
NKE Nike
$101.46 /

+1.37 (+1.37%)

06/23/20 Susquehanna
Nike price target raised to $130 from $100 at Susquehanna
06/23/20 Needham
Nike price target raised to $113 from $80 at Needham
06/23/20 BTIG
Nike price target raised to $117 from $108 at BTIG
06/22/20 JPMorgan
Nike price target raised to $104 from $91 at JPMorgan
SOLY Soliton
$11.82 /

-0.18 (-1.50%)

06/16/20 Roth Capital
Soliton price target raised to $16 from $14 at Roth Capital
03/27/20
Fly Intel: Top five analyst initiations
03/27/20 Roth Capital
Soliton initiated with a Buy at Roth Capital
12/05/19 Maxim
Soliton initiated with a Buy at Maxim
MTCH Match Group
$98.99 /

+0.96 (+0.98%)

06/23/20 SunTrust
SunTrust raises price targets on IAC, Angi Homeservices, Match Group
06/23/20 BMO Capital
Angi Homeservices price target raised to $16 from $10 at BMO Capital
06/23/20 BMO Capital
IAC price target raised to $369 from $316 at BMO Capital
06/23/20 BMO Capital
Match Group price target raised to $95 from $85 at BMO Capital
SOLY Soliton
$11.82 /

-0.18 (-1.50%)

SNX Synnex
$101.60 /

-1.175 (-1.14%)

PRGS Progress Software
$37.94 /

+1.16 (+3.15%)

NKE Nike
$101.46 /

+1.37 (+1.37%)

MTCH Match Group
$98.99 /

+0.96 (+0.98%)

INO Inovio
$31.33 /

+7.425 (+31.07%)

DKNG DraftKings
$36.07 /

-1.48 (-3.94%)

CAMP CalAmp
$7.69 /

+0.15 (+1.99%)

  • 26
    Jun
NKE Nike
$101.46 /

+1.37 (+1.37%)

MTCH Match Group
$98.99 /

+0.96 (+0.98%)

INO Inovio
$31.33 /

+7.425 (+31.07%)

DKNG DraftKings
$36.07 /

-1.48 (-3.94%)

SNX Synnex
$101.60 /

-1.175 (-1.14%)

PRGS Progress Software
$37.94 /

+1.16 (+3.15%)

NKE Nike
$101.46 /

+1.37 (+1.37%)

MTCH Match Group
$98.99 /

+0.96 (+0.98%)

INO Inovio
$31.33 /

+7.425 (+31.07%)

DKNG DraftKings
$36.07 /

-1.48 (-3.94%)

CAMP CalAmp
$7.69 /

+0.15 (+1.99%)

SNX Synnex
$101.60 /

-1.175 (-1.14%)

NKE Nike
$101.46 /

+1.37 (+1.37%)

MTCH Match Group
$98.99 /

+0.96 (+0.98%)

INO Inovio
$31.33 /

+7.425 (+31.07%)

DKNG DraftKings
$36.07 /

-1.48 (-3.94%)

CAMP CalAmp
$7.69 /

+0.15 (+1.99%)

Syndicate
Soliton files to sell common stock, no amount given » 16:02
06/25/20
06/25
16:02
06/25/20
16:02
SOLY

Soliton

$11.79 /

-0.21 (-1.75%)

Cantor Fitzgerald &…

Cantor Fitzgerald & Co. is acting as the sole book-running manager for the proposed offering.

ShowHide Related Items >><<
SOLY Soliton
$11.79 /

-0.21 (-1.75%)

SOLY Soliton
$11.79 /

-0.21 (-1.75%)

06/16/20 Roth Capital
Soliton price target raised to $16 from $14 at Roth Capital
03/27/20
Fly Intel: Top five analyst initiations
03/27/20 Roth Capital
Soliton initiated with a Buy at Roth Capital
12/05/19 Maxim
Soliton initiated with a Buy at Maxim
SOLY Soliton
$11.79 /

-0.21 (-1.75%)

Recommendations
Soliton price target raised to $16 from $14 at Roth Capital » 09:56
06/16/20
06/16
09:56
06/16/20
09:56
SOLY

Soliton

$14.25 /

-0.23 (-1.59%)

Roth Capital analyst…

Roth Capital analyst Scott Henry raised the firm's price target on Soliton to $16 from $14 and keeps a Buy rating on the shares citing the "robust" pivotal results for the company's developmental non-invasive cellulite treatment. The data matched already high expectations as ~92% of patients believed that they had improvement after only one treatment, Henry tells investors in a research note. Soliton expects to file a 510K in June with potential approval in late 2020/early 2021, the analyst adds.

ShowHide Related Items >><<
SOLY Soliton
$14.25 /

-0.23 (-1.59%)

SOLY Soliton
$14.25 /

-0.23 (-1.59%)

03/27/20
Fly Intel: Top five analyst initiations
03/27/20 Roth Capital
Soliton initiated with a Buy at Roth Capital
12/05/19 Maxim
Soliton initiated with a Buy at Maxim
SOLY Soliton
$14.25 /

-0.23 (-1.59%)

Hot Stocks
Soliton reports 'positive' pivotal cellulite clinical trial results » 08:02
06/15/20
06/15
08:02
06/15/20
08:02
SOLY

Soliton

$13.89 /

+1.35 (+10.77%)

Soliton announced that…

Soliton announced that new positive data from the company's pivotal cellulite clinical trial was presented in an oral presentation via the American Academy of Dermatology 2020 VMX Virtual Conference on June 12. "We are pleased that our pivotal cellulite study demonstrated positive results and appreciate the opportunity to have our findings presented through this prestigious dermatology organization," stated Christopher Capelli, MD, founder, President and CEO of Soliton. "In addition to demonstrating an average 32.5% improvement in the Cellulite Severity Score in our subjects, patient satisfaction was strong with 91.9% of subjects agreeing or strongly agreeing that their cellulite appeared improved. Further, there were no unexpected or serious adverse events and the average pain scores were 2.4 on a 10-point scale."

ShowHide Related Items >><<
SOLY Soliton
$13.89 /

+1.35 (+10.77%)

SOLY Soliton
$13.89 /

+1.35 (+10.77%)

03/27/20
Fly Intel: Top five analyst initiations
03/27/20 Roth Capital
Soliton initiated with a Buy at Roth Capital
12/05/19 Maxim
Soliton initiated with a Buy at Maxim
SOLY Soliton
$13.89 /

+1.35 (+10.77%)

Over a month ago
Earnings
Soliton reports Q1 EPS (19c), consensus (25c) » 07:32
05/14/20
05/14
07:32
05/14/20
07:32
SOLY

Soliton

$9.20 /

-0.335 (-3.52%)

Total cash was $7.7M as…

Total cash was $7.7M as of March 31, vs. $12.1M as of December 31, 2019. Cash, cash equivalents and restricted cash on hand is sufficient to fund operations into December but not beyond. CEO Chris Capelli commented, "Although Q1 was largely governed by the unprecedented COVID-19 pandemic, Soliton continued to achieve a number of significant milestones, including FDA clearance of the Special 510(k) premarket notification for the Generation II RAP device and the completion of both the 12-week keloid and hypertrophic scar proof-of-concept study and the pivotal cellulite clinical trial. We plan to present the results of the cellulite trial at the virtual AAD Conference expected to be held in mid-June 2020. The results of this study will support our anticipated 510(k) filing with the FDA for the treatment of cellulite during Q2. Our focus remains on executing our revised U.S. commercialization plans, adapted as a result of the COVID-19 crisis and now strategically incorporating both tattoo removal and cellulite treatment into a Generation II RAP device. We remain optimistic the aesthetic and financial markets will recover and look forward to providing details of our future U.S. commercial launch once conditions have stabilized for our dermatology customers."

ShowHide Related Items >><<
SOLY Soliton
$9.20 /

-0.335 (-3.52%)

SOLY Soliton
$9.20 /

-0.335 (-3.52%)

03/27/20
Fly Intel: Top five analyst initiations
03/27/20 Roth Capital
Soliton initiated with a Buy at Roth Capital
12/05/19 Maxim
Soliton initiated with a Buy at Maxim
Hot Stocks
Soliton granted patent for FDA cleared RAP technology » 08:03
04/08/20
04/08
08:03
04/08/20
08:03
SOLY

Soliton

$7.60 /

-0.4 (-5.00%)

Soliton has been issued a…

Soliton has been issued a patent by the USPTO titled "Rapid Pulse Electrohydraulic Shockwave Generator Apparatus and Methods for Medical and Cosmetic Treatments". The company's first planned commercial product is designed to use rapid pulses of designed acoustic shockwaves in conjunction with existing lasers to accelerate the removal of unwanted tattoos - RAP device -. In addition, higher energy versions of acoustic pulse devices are in early stages of development for potential stand-alone treatment of cellulite and other indications. The RAP device uses electrohydraulics to generate the designed acoustic shockwaves at a rate of up to 100 per second to effectively target differences in density at the cellular level.

ShowHide Related Items >><<
SOLY Soliton
$7.60 /

-0.4 (-5.00%)

03/27/20
Fly Intel: Top five analyst initiations
03/27/20 Roth Capital
Soliton initiated with a Buy at Roth Capital
12/05/19 Maxim
Soliton initiated with a Buy at Maxim
Over a quarter ago
Hot Stocks
Soliton postpones launch of RAP tattoo removal device » 08:07
04/01/20
04/01
08:07
04/01/20
08:07
SOLY

Soliton

$7.95 /

-0.48 (-5.69%)

Soliton provided an…

Soliton provided an update on its business strategy and financial position in light of the current COVID-19 situation. CEO Christopher Capelli commented, "(...) Instead of launching our RAP device focused solely on tattoo removal in mid-2020, we are electing to delay that launch until the aesthetic and financial markets are demonstrating more stability. In the meantime, we will remain highly focused on our regulatory pathway for cellulite reduction. We now believe our initial launch could be timed appropriately to incorporate both tattoo and cellulite indications, subject to FDA clearance of the latter. (...)" At this time, Soliton does not anticipate a delay in its regulatory plans for the cellulite indication and plan to file its 510(k) in Q2. Follow-up visit cancellations in the ongoing 26-week cellulite assessment and increased difficulty in executing the initiation of further clinical trials at sites around the country will impact the timing of Soliton's planned additional hypertrophic scar proof-of-concept study and the longer-term 26-week follow-up visits in its cellulite pivotal study. Furthermore, it is possible this may extend the time required to file for additional, improved cellulite reduction claims with the FDA. Soliton now expects cash on hand to finance operations to December 2020.

ShowHide Related Items >><<
SOLY Soliton
$7.95 /

-0.48 (-5.69%)

03/27/20
Fly Intel: Top five analyst initiations
03/27/20 Roth Capital
Soliton initiated with a Buy at Roth Capital
12/05/19 Maxim
Soliton initiated with a Buy at Maxim

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.